Table 2.
Demographic and clinical characteristics of IBD patients with incident CRC.
| Kerrypnx | Total (n = 56) | UC (n = 34) | CD (n = 22) | p (Yates) |
|---|---|---|---|---|
| Gender (F) n (%) | 20 (35.7%) | 9 (26.4%) a | 11 (50%) | 0.13 |
| Age at CRC diagnosis, median (range) | 55.5 (22–76) | 59 (22–76) | 53 (32–76) | 0.46 |
| IBD duration at CRC, median (range) | 15.5 (1–44) | 17 (1–35) | 13.5 (1–44) | 0.97 |
| IBD related surgery, n (%) | 11 (19.6%) | 2 (5.9%) | 9 (40.9%) | 0.002 |
| Time interval from diagnosis of IBD to last visit/death (yrs), median (range) (n = 50) | 1 (0–21) | 1 (0–9) | 1 (0–21) | 0.37 |
| Time interval from diagnosis of IBD to CRC-related death (years), mean (range) (n = 16) | 15.5 (1–45) | 18.5 (1–28) | 12.5 (2–45) | 0.89 |
| Time interval from diagnosis of CRC and CRC-related death (months), mean (range) (n = 16) | 12 (1–68) | 6.5 (1–68) | 14.5 (8–40) | 0.85 |
| Time interval between CRC diagnosis and death/loss at follow up (years), mean (range) | 2 (0–41) | 2 (0–41) | 1.5 (0–21) | 0.60 |
| Perianal disease, n (%) | 11 (19.6%) | 2 (5.9%) | 9 (40.9%) | 0.004 |
| Smoking (yes), n (%) | 4 (7.1%) | 2 (5.8%) | 2 (9.1%) | 0.98 |
| Appendectomy, n (%) | 6 (10.7%) | 4 (11.7%) | 2 (9.1%) | 0.89 |
| EIMs, n (%) | 7 (12.5%) | 4 (11.7%) | 3 (13.6%) | 0.83 |
| Comorbidities, n (%) | 24 (42.8%) | 13 (38.2%) | 11 (50%) | 0.55 |
| Family history CRC, n (%) | 0.6 | |||
| yes | 5 (8.9%) | 2 (5.8%) | 3 (13.6%) | |
| no | 46 (82.2%) | 27 (79.4%) | 19 (86.4%) | |
| unknown | 5 (8.9%) | 5 (14.7%) | 0 (0%) | |
| History of adenomas, n (%) | 7 (12.5%) | 4 (11.7%) | 3 (13.6%) | 0.83 |
| CD behavior, n (%) | ||||
| B1 | - | - | 10 (45.5%) | |
| B2 | - | - | 5 (22,7%) | |
| B3 | - | - | 7 (31.8%) | |
| CD location, n (%) | ||||
| L1 | - | - | 7 (31.8%) | |
| L2 | - | - | 4 (18.2%) | |
| L3 | - | - | 10 45.5%) | |
| L4 | - | - | 1 (4.5%) | |
| UC extent, n (%) | ||||
| E1 | - | 0 (0%) | - | |
| E2 | - | 13 (38.2%) | - | |
| E3 | - | 21 (61.8%) | - | |
| Previous or ongoing ISS, n (%) | 19 (33.9%) | 11 (32.3%) | 8 (36.4%) | 0.98 |
| Thiopurines | 19 (33.9%) | 11 (32.3%) | 8 (36.4%) | 0.98 |
| Methotrexate | 2 (3.5%) | 0 (0%) | 2 (9.1%) | 0.29 |
| Previous or ongoing biologics, n (%) | 18 (32.1%) | 8 (22.2%) | 10 (45.5%) | 0.15 |
| Infliximab | 14 (25%) | 6 (16.6%) | 8 (36.4%) | 0.20 |
| Adalimumab | 6 (10.7%) | 2 (5.5%) | 4 (18.2%) | 0.31 |
| Certolizumab | 1 (1.8%) | 0 (0%) | 1 (4.5%) | 0.82 |
Abbreviations. IBD: Inflammatory Bowel Disease; UC: Ulcerative Colitis; CD: Crohn’s Disease; CRC: colorectal cancer; EIMs: Extraintestinal manifestations; B1: non-penetrating non-stricturing, B2: stricturing, B3: penetrating; L1: ileal, L2: colonic, L3 ileum-colonic, L4, upper gastro-intestinal tract; E1: proctitis, E2: left-sided colitis, E3: extended colitis; ISS: conventional immunosuppressors.